During the corresponding time, Transmedics Group Inc recorded a revenue increase by 20.7 % year on year, sequentially revenue grew by 9.21 %. While revenue at the Transmedics Group Inc 's corporate clients
Transmedics Group Inc's Comment on Sales, Marketing and Customers
The company provides services to customers involved in organ transplantation, specifically those using the Organ Care System (OCS) technology. Its customers include transplant centers that have relocated but continue utilizing the OCS, leveraging the company's expertise in transplant reimbursement and billing with the Centers for Medicare & Medicaid Services (CMS) and private insurers. The company serves market segments focused on organ transplant therapy for end-stage organ failure, particularly heart transplantation, which is considered superior to optimum medical management (OMM) and left ventricular assist devices (LVADs). It addresses challenges related to organ preservation and post-transplant complications, aiming to improve patient outcomes and increase the annual number of transplant procedures through advanced organ preservation technology.
In a noteworthy development for TransMedics Group, Inc. (NASDAQ: TMDX), investors have been alerted to a pending class action lawsuit, with a lead plaintiff deadline set for April 15, 2025. The Gross Law Firm, representing the interests of affected shareholders, has issued a formal announcement to notify stakeholders about the lawsuit, signaling potential legal turbulence on the horizon for the innovative medical technology company. The Underlying FactsTransMedics Group, a company known for its groundbreaking work in organ transplantation, particularly concerning its Organ Care System, has garnered significant attention on the stock market since its initial public offering. However, the emergence of this cla...
Report: TransMedics Group, Inc. a company listed on the NASDAQ under the ticker symbol TMDX, is currently under investigation by The Rosen Law Firm, a prominent global investor rights law firm. The investigation pertains to potential securities claims on behalf of shareholders who may have experienced financial losses as a result of the company’s alleged dissemination of materially misleading business information to the public.On January 25, 2025, The Rosen Law Firm announced its ongoing investigation, emphasizing the firm’s commitment to exploring the rights of investors affected by TransMedics actions. While specific details regarding the misleading information have not yet been disclosed publicly, t...
Transmedics Group Inc’s Comment on Sales, Marketing and Customers
The company provides services to customers involved in organ transplantation, specifically those using the Organ Care System (OCS) technology. Its customers include transplant centers that have relocated but continue utilizing the OCS, leveraging the company's expertise in transplant reimbursement and billing with the Centers for Medicare & Medicaid Services (CMS) and private insurers. The company serves market segments focused on organ transplant therapy for end-stage organ failure, particularly heart transplantation, which is considered superior to optimum medical management (OMM) and left ventricular assist devices (LVADs). It addresses challenges related to organ preservation and post-transplant complications, aiming to improve patient outcomes and increase the annual number of transplant procedures through advanced organ preservation technology.
Sources:
Transmedics Group Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Transmedics Group Inc’s corporate clients.
For your research, we’ve provided 9 tables on Transmedics Group Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
115.36 %